Barinthus Biotherapeutics

Company snapshot

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics. With a broad pipeline, built around four

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Barinthus Biotherapeutics. Not investment advice.

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 40

• Peer + 0 momentum

  Lxo Ireland Designated

  TA overlap score 33.6

• Peer + 0 momentum

  Arrowhead Pharmaceuticals Ireland

  TA overlap score 32.6

• Peer + 0 momentum

  INOVIO Pharmaceuticals

  TA overlap score 29.2

• Peer + 0 momentum

  Green Valley Pharmaceutical

  TA overlap score 21

Recent activity

Latest pipeline, patent, and corporate events for Barinthus Biotherapeutics.

1. Jun 8, 2026 Clinical update

   Seasonal influenza vaccine — Phase 2

2. Jun 8, 2026 Clinical update

   MVA-NP+M1 — Phase 2

3. Jun 8, 2026 Clinical update

   ChAdOx1-HBV — Phase 2

4. Jun 5, 2026 Clinical update

   ChAdOx1-MVA 5T4 vaccine — Phase 2

5. May 23, 2026 Clinical update

   ChAdOx1-HBV — Phase 2

View all clinical trial activity →

• What is Barinthus Biotherapeutics?

  Barinthus Biotherapeutics is a pharma organization headquartered in Harwell, GB. It trades on NYSE under ticker BRNS. Primary therapeutic focus areas include Influenza, Celiac Disease, Chronic Hepatitis B, Hepatitis B, HPV Infection. NovaPharmaNews links 9 clinical program(s), 0

• Is Barinthus Biotherapeutics publicly traded?

  Yes. Barinthus Biotherapeutics is listed with ticker BRNS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Barinthus Biotherapeutics develop or market?

  We link 5 drug profile(s) where Barinthus Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/barinthus-biotherapeutics-plc#company-drugs.

• What are the latest developments for Barinthus Biotherapeutics?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Barinthus Biotherapeutics focus on?

  Barinthus Biotherapeutics focuses on Influenza, Celiac Disease, Chronic Hepatitis B based on our analysis of their pipeline programs and drug development activities.